Solid silver MedImmune backs cancer charity
MedImmune, the global biologics research and development arm of AstraZeneca, has marked its 25th anniversary and expansion in the Cambridge medical technology cluster with a major donation to Macmillan Cancer Support.
MedImmune was founded in 1988 and has built on the local legacy of Cambridge Antibody Technology.
The company’s pioneering research has led to ground-breaking achievements, including the development and commercialisation of Synagis® (palivizumab) and Fluenz® (nasal spray, suspension influenza vaccine [live attenuated]).
MedImmune discoveries have also helped lead to a human papillomavirus vaccine, the important anti-tumour necrosis factor (TNF) antibody and the first active systemic lupus erythematosus treatment in decades.
Jane Osbourn, site leader and vice-president of R & D at MedImmune in Cambridge, said: “As part of our 25th anniversary celebrations, MedImmune has made a £3,200 donation to the Macmillan Cancer Support, which was an organisation selected by Cambridge employees.
“MedImmune is committed to discovering novel treatments in oncology, one of the company’s core therapeutic areas. As one of the largest biotechnology companies in Cambridge, MedImmune’s Cambridge site employs more than 500 people and is a significant contributor to the local economy and local life science sector.
“We are committed to the Cambridge community, and look forward to continuing to play a leading role which will be strengthened by the arrival of colleagues from AstraZeneca.”
Carla Pilsworth, Cambridge Fundraising Manager for Macmillan Cancer Support, added: “We are immensely grateful to the team at MedImmune for selecting our charity. With treatments improving and the population ageing, more people are living with the illness than ever before.
“Our ambition is to reach and improve the lives of everyone affected by cancer, no matter who they are or where they live and inspire millions to do the same.
“In Cambridgeshire we fund over 90 medical professionals including nurses, GPs, dieticians and speech and language therapists. The money that has been so generously given by MedImmune will help us to maintain our vital support services.”
• PHOTOGRAPH: Carla Pilsworth from MacMillan Cancer Support receives MedImmune’s donation from members of the MedImmune team (left to right) Apple Siladaj, Ruth Franks, Jennifer Spooner, Christel Navarro and Jane Osbourn.